Banner
Browse by multiple fields below

Download csv Download xlsx
PDX ID Sample ID Patient Id Sample Site Sample Source Age Sample Collected PSA at diagnosis (ng/mL) Gleason Score Primary Gleason Score Secondary Gleason Score Grade Group Tumour Grade D'Amico Risk Classification Primary Tumour Volume (cc) Treatment Prior to Specimen Collection PDX Host Type PDX Graft Site Current PDX Generation Average PDX Generation Time (days ± SEM) Tumour preparation2 Pubmed ID
407M Cx 407M 407 Liver Biopsy 75-79 NA 0.0 ADT, docetaxel, abiraterone, enzalutamide Castrate Subcutaneous 9 (5*) 128 ± 30 Tumor solid 34413304
410.51A 410.51A 410 Right lung sub pleural tumour Autopsy 70-74 30 0.0 ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide Testosterone supplemented Subcutaneous 11 60 ± 7 Tumor solid 34413304
410.51A Cx 410.51A 410 Right lung sub pleural tumour Autopsy 70-74 30 0.0 ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide Castrate Subcutaneous 10 (6*) 108 ± 9 Tumor solid 34413304
422M 422M 422 Brain Surgery 70-74 NA 0.0 ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide Testosterone supplemented Subcutaneous 11 62 ± 4 Tumor solid 34413304
422M Cx 422M 422 Brain Surgery 70-74 NA 0.0 ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide Castrate Subcutaneous 7 (2*) 184 ± 72 Tumor solid 34413304
424M 424M 424 Lymph node Biopsy 75-79 NA 0.0 ADT, zoladex and cosudex Testosterone supplemented Subcutaneous 6 136 ± 38 Tumor solid 34413304
435.1A 435.1A 435 Right temporal fossa Autopsy 65-69 16.2 0.0 ADT, carboplatin plus etoposide Testosterone supplemented Subcutaneous 5 51 ± 3 Tumor solid 34413304
435.1A Cx 435.1A 435 Right temporal fossa Autopsy 65-69 16.2 0.0 ADT, carboplatin plus etoposide Castrate Subcutaneous 17 (13*) 56 ± 2 Tumor solid 34413304